FREE Shipping over $49 - Potential Port Container Delay
Cart 0

Vanguard Plus 5/4L, Green, Box 25 -
Roll over to zoom
Vanguard Plus 5/4L, Green, Box 25
by Pfizer Animal Health

FREE SHIPPING within Contiguous U.S.
$146.76 $161.00 (9% off)
Item #: PMD-10374
Ship Weight: 0.679 lb
10+ in stock

Our Guarantee
30-Day Returns     No Restock Fee     Hassle Free Returns

We Accept Paypal, VISA, Mastercard, American Express, and Discover


This is an over the counter product - it does not require prescription.

Ships on ICE, Please choose 2nd day Shipping for this item. For Canada customers, please choose Worldwide Saver as the shipping method.

The vaccine component of VANGUARD® Plus 5/L contains attenuated strains of CD virus, CAV-2, CPI virus, and CPV propagated on an established canine cell line. The CPV fraction is high titer (107.0 TCID50/dose) and was attenuated by low passage (35 passes from the canine isolate with a maximum of 2 additional passes allowed for production) on the canine cell line which gives it the immunogenic properties capable of overriding maternal antibody interference at the levels indicated in Table 2. Some puppies in the field may have higher levels of maternal antibodies than those evaluated in our pivotal efficacy study. The vaccine is packaged in freeze-dried form with inert gas in place of vacuum. The bacterin component, containing inactivated whole cultures of L. canicola and L. icterohaemorrhagiae, is supplied as diluent.

Contains penicillin and streptomycin as preservatives.

Indications: VANGUARD® Plus 5/L is for vaccination of healthy dogs 6 weeks of age or older as an aid in preventing canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, canine parvoviral enteritis caused by canine parvovirus (CPV), and leptospirosis caused by Leptospira canicola and L. icterohaemorrhagiae.


1. General Directions: Vaccination of healthy dogs is recommended. Aseptically rehydrate the freeze-dried vaccine (VANGUARD® Plus 5) with the liquid bacterin provided (Leptoferm C-I®), shake well, and administer 1 mL subcutaneously or intramuscularly.
2. Primary Vaccination: Healthy dogs 6 weeks of age or older should receive 3 doses, each administered 3 weeks apart.
3. Revaccination: Annual revaccination with a single dose is recommended.

Precaution(s): Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

Use entire contents when first opened.

Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.

Burn containers and all unused contents.

Caution(s): Vaccination of pregnant bitches should be avoided.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

For use in dogs only.

Warning(s): For veterinary use only.

Disease Description: CD is a universal, high-mortality viral disease with variable manifestations. Approximately 50% of nonvaccinated, nonimmune dogs infected with CD virus develop clinical signs, and approximately 90% of those dogs die.1 ICH, caused by CAV-1, is a universal, sometimes fatal, viral disease of dogs characterized by hepatic and generalized endothelial lesions. CAV-2 causes respiratory disease which in severe cases may include pneumonia and bronchopneumonia. CPI is a common viral upper respiratory disease. Uncomplicated CPI may be mild or subclinical, with signs becoming more severe if concurrent infection with other respiratory pathogens exists. CPV infection results in enteric disease characterized by sudden onset of vomiting and diarrhea, often hemorrhagic. Leukopenia commonly accompanies clinical signs. Susceptible dogs of any age can be affected, but mortality is greatest in puppies. In puppies 4-12 weeks of age CPV may occasionally cause myocarditis that can result in acute heart failure after a brief and inconspicuous illness. Following infection many dogs are refractory to the disease for a year or more. Similarly, seropositive bitches may transfer to their puppies CPV antibodies which can interfere with active immunization of the puppies through 16 weeks of age. Leptospirosis occurs in dogs of all ages, with a wide range of clinical signs and chronic nephritis generally following acute infection. Infection with L. canicola and L. icterohaemorrhagiae cannot be differentiated clinically.

Trial Data: Safety and Efficacy: Laboratory evaluation demonstrated that VANGUARD® Plus 5/L immunized dogs against CD, ICH, CAV-2 respiratory disease, CPI, CPV, and leptospirosis caused by L. canicola and L. icterohaemorrhagiae, and that no immunologic interference existed among the vaccine fractions. Extensive field safety trials conducted by Pfizer Animal Health showed it to be safe and reaction-free in dogs as young as 6 weeks of age under normal usage conditions.

It has been demonstrated that CAV-2 vaccine cross-protects against ICH caused by CAV-1. The CAV-2 fraction in Vanguard® vaccines is used as a replacement for CAV-1 because it has significant advantages. Some CAV-1 vaccines may produce undesirable reactions, including persistent kidney infections, uveitis, and corneal opacity ("blue eye"), which have not been reported after vaccination with CAV-2.2 In addition, the CAV-2 strain used in Vanguard® vaccines has been specially selected for freedom from oncogenic properties characteristic of adenoviruses.

Studies conducted at Pfizer demonstrated that CAV-2 not only protects against ICH, but against CAV-2 respiratory disease as well.3 Although conventional CAV-1 (ICH) vaccines cross-protect against CAV-2, they may not prevent subclinical infection and spread of the CAV-2 agent. Canine adenovirus type 2 challenge virus was not recovered from CAV-2-vaccinated dogs in tests conducted at Pfizer

Featured Collections

View all Collections

Questions & Answers

Have a Question?

Be the first to ask a question about this.

Ask a Question

Customer Reviews

Sponsored Ad